{"id":"NCT00337779","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).","officialTitle":"A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2006-06-16","resultsPosted":"2010-05-14","lastUpdate":"2011-10-10"},"enrollment":1155,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Remitting Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Glatiramer Acetate (GA) 40 mg","otherNames":["Copaxone®"]},{"type":"DRUG","name":"glatiramer acetate 20 mg","otherNames":["Copaxone®"]}],"arms":[{"label":"glatiramer acetate 40 mg","type":"ACTIVE_COMPARATOR"},{"label":"glatiramer acetate 20 mg","type":"ACTIVE_COMPARATOR"}],"summary":"Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of R-R MS. GA is an immunomodulating drug that has anti inflammatory and neuroprotective properties. The study treatment duration is 12 months.","primaryOutcome":{"measure":"The Rate of Confirmed Relapses During the Double-blind Phase (12 Months).","timeFrame":"12 months","effectByArm":[{"arm":"Glatiramer Acetate 20 mg","deltaMin":0.28,"sd":0.58},{"arm":"Glatiramer Acetate 40 mg","deltaMin":0.27,"sd":0.54}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4859"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":586},"commonTop":["Injection Erythema","Injection Site Pain","Injection Site Pruritus","Nasopharyngitis","Headache"]}}